Stock listing
Scancell Holdings Plc
Selected listing: SCLP · LSE · GBX · GB
Scancell Holdings Plc (LSE:SCLP), Health Technology. Latest release Oct 2, 2026: Notice of GM.
- Ticker
- LSE:SCLP
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LSE
- Currency
- GBX
About Scancell Holdings Plc
The company focuses on developing innovative immunotherapies for cancer treatment. Scancell aims to advance its proprietary technologies to improve patient outcomes in oncology.
Latest news from Scancell Holdings Plc
Notice of GM
October 2, 2026
Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development
September 24, 2026
Scancell to Present at the H.C. Wainwright Sept 26
September 3, 2026
iSCIB1+ MHRA CTA Approval for Ph3 trial
August 19, 2026
Extension of Option Exercise Period
July 31, 2026
Events
Replays
SCANCELL HOLDINGS PLC (SCLP) — Clinical and Corporate Update
Wed, Jun 25, 2025 · 06:00 AM ET
Watch
Research Scancell Holdings Plc
Scancell Holdings Plc company profile
View the public company page for Scancell Holdings Plc on 6ix.
Scancell Holdings Plc news
Read company news and market updates connected to Scancell Holdings Plc.
Scancell Holdings Plc investor events
Find investor webinars, events, and replay context for Scancell Holdings Plc.
Alternate listings
SCNLF:OTC
US · USD
Alternate listing for Scancell Holdings Plc; the primary context on this page is SCLP:LSE.
SCLP.GB:AQUIS
GB · GBX
Alternate listing for Scancell Holdings Plc; the primary context on this page is SCLP:LSE.
SCP:FWB
DE · EUR
Alternate listing for Scancell Holdings Plc; the primary context on this page is SCLP:LSE.